# Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

- Link: https://www.thailand-business-news.com/pr-news/accro-bioscience-announces-inclusion-of-ac-101-tablets-in-the-nmpa-cdes-caring-plan-extension-pilot-program-for-rare-disease-drug-development
- Published: 2026-09-14T09:00:00+07:00
- Author: PR Newswire

NEW YORK and SUZHOU, China, Sept. 14, 2026 /PRNewswire/ — On September 14, 2026 (
China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have
been included in the Rare Diseases Innovative Drug Development Encouragement Pilot
Program (the "Caring Plan-Extension", known in Chinese as "关爱计划-延伸" of the
Center for Drug Evaluation (CDE) of China’s National Medical Products Administration(
NMPA), with Blau syndrome as the proposed indication. The relevant public notice
period ended on September 11, 2026. Previously, in June 2026, the U.S. Food and 
Drug Administration (FDA) granted AC-101 Rare Pediatric Disease (RPD) designation
for the treatment of Blau syndrome (BS).

**About AC-101**

AC-101 is a novel, selective RIPK2 inhibitor derived from Accro Bioscience’s proprietary
drug discovery platform targeting regulatory cell death and inflammation. It is 
being developed for the treatment of moderate-to-severe ulcerative colitis (UC).
Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling
pathway, and dysregulation of NOD/RIPK2 signaling is associated with multiple inflammatory
and autoimmune diseases, including inflammatory bowel disease (IBD). AC-101 has 
completed Phase I studies in healthy volunteers in Australia and China, demonstrating
favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese
patients with moderate-to-severe UC has been completed. The efficacy and safety 
results from this study will be presented at UEG Week 2026. For details, please 
see the [related press release](https://www.accropeutics.com/news/116.html).

**About Blau Syndrome**

Blau syndrome is a rare hereditary autoinflammatory disease caused by pathogenic
variants in the NOD2 gene. It usually begins in early childhood and can involve 
multiple systems, including the skin, joints and eyes. Its classic clinical presentation
is the triad of granulomatous dermatitis, arthritis and uveitis. Joint involvement
may lead to joint deformity and functional impairment over time. Ocular involvement
can cause uveitis; if not controlled promptly, it may lead to severe visual impairment
or even blindness.^([1,2])

**About Accro Bioscience**

Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery,
development and commercialization of novel therapeutics for inflammatory and autoimmune
diseases, by targeting molecular mechanisms of regulatory cell death. The company’s
robust pipeline of first- and best-in-class compounds offers the potential to bring
innovative, paradigm-shifting therapies to patients.

For more information, please visit [www.accropeutics.com](http://www.accropeutics.com/).

[1]. [NIH/NLM MedlinePlus Genetics — Blau syndrome](https://medlineplus.gov/genetics/condition/blau-syndrome/)

[2]. [NIH/NLM MeSH — Blau syndrome](https://www.ncbi.nlm.nih.gov/mesh/67538157)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development ](http://www.prnasia.com/story/archive/5046659_CN46659_0?rand=184833)